GRTX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 04:00):

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer...

Stats
今日成交量	322 228
平均成交量	2.08M
市值	9.63M
EPS	$0 ( 2024-05-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.130
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Schneid Yair	Buy	99 371	Common Stock
2024-04-19	Schneid Yair	Buy	215	Common Stock
2024-04-19	Schneid Yair	Buy	314	Common Stock
2024-04-19	Schneid Yair	Buy	100	Common Stock
2024-04-18	Schneid Yair	Buy	74 202	Common Stock

INSIDER POWER
99.83
Last 95 transactions
Buy: 7 344 028 \| Sell: 846 527

音量相关性

長: 0.08 (neutral)

短: -0.06 (neutral)

Signal:(38.275) Neutral

Galera Therapeutics Inc 相关性

10 最正相关
LIAN	0.848
IMAB	0.843
MEUSW	0.842
PXLW	0.841
ADXN	0.839
LEGO	0.833
FORA	0.828
VYGR	0.814

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Galera Therapeutics Inc 相关性 - 货币/商品

0.00
( neutral )

-0.43
( neutral )

Galera Therapeutics Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-259 000 (0.00 %)
EPS:	$-1.330

FY	2023
营收:	$0
毛利润:	$-259 000 (0.00 %)
EPS:	$-1.330

FY	2022
营收:	$0
毛利润:	$-114 000 (0.00 %)
EPS:	$-2.30

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-3.06

Financial Reports:

No articles found.

Galera Therapeutics Inc

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.